More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$6.66B
EPS
-1.08
P/E ratio
--
Price to sales
67.19
Dividend yield
--
Beta
0.181388
Previous close
$5.98
Today's open
$6.12
Day's range
$6.08 - $6.38
52 week range
$1.95 - $12.43
show more
CEO
Richard Adcock
Employees
691
Headquarters
San Diego, CA
Exchange
Nasdaq Global Select
Shares outstanding
1.06B
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
ImmunityBio, Inc. (IBRX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript
ImmunityBio, Inc. ( IBRX ) UBS Global Biopharma Conference 2026 November 16, 2026 5:40 AM EST Company Participants Richard Adcock - President, CEO & Director Conference Call Participants Dejia Zhang Presentation Dejia Zhang My name is Dejia Zhang, and I am part of the UBS coverage team. We're very excited to host this first inaugural biotech conference here in London.
Seeking Alpha • Nov 16, 2026

New U.S. Survey of Military Service Members and Veterans with Non-Muscle Invasive Bladder Cancer Reveals 53% Were Diagnosed at Age 50 or Younger and Barriers to Care
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced findings from a national survey of military service members and veterans with non-muscle invasive bladder cancer (NMIBC). The survey, conducted by The Harris Poll on behalf of ImmunityBio, found that 53% of respondents were diagnosed by age 50 and 63% reported barriers or challenges to receiving treatment. Respondents reported a mean age of 51.7 years at diagnosis (m.
Business Wire • Nov 11, 2026

IBRX Q3 Earnings Miss, Anktiva Sales Decline Q/Q, Stock Down 18%
ImmunityBio's revenues jump 53% on Anktiva adoption, but a wider-than-expected loss, sequential sales decline and rising expenses weigh on shares.
Zacks Investment Research • Nov 10, 2026

ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced members of the senior leadership team will speak at the upcoming Jefferies Global Healthcare Conference and the UBS Global Biopharma Conference, both held in London during Life Sciences Week 2026, November 15-20. “The results from our QUILT-2.005 study bring us closer to our goal of treating bladder cancer earlier in the course of the disease,” said Richard Adcock, P.
Business Wire • Nov 11, 2026

ImmunityBio Reports Wider Quarterly Loss
ImmunityBio Inc. (NASDAQ:IBRX) stock is trading lower on Monday after the company's third-quarter earnings missed expectations.
Benzinga • Nov 9, 2026

Why ImmunityBio Stock Dropped 15% After Earnings Despite 53% Sales Growth. Is IBRX Now a Buy?
ImmunityBio's quarterly product sales rose 53% from a year earlier, but they slipped from the prior quarter and missed Wall Street's estimate. Even after Monday's drop, the stock trades at roughly 39 times its annualized sales, and the company says there is "substantial doubt" about its ability to continue without additional funding.
The Motley Fool • Nov 9, 2026

ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced continued global expansion, expanded FDA approval, and financial results for the third quarter ended September 30, 2026. ImmunityBio continued to advance a broad clinical pipeline spanning bladder cancer, non-small cell lung cancer, and hematologic malignancies with expanded FDA approval and global expansion of ANKTIVA in nonmuscle invasive bladder cancer (NMIBC). AN.
Business Wire • Nov 9, 2026

ImmunityBio (IBRX) Reports Q3 Loss, Misses Revenue Estimates
ImmunityBio (IBRX) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.07 per share a year ago.
Zacks Investment Research • Nov 9, 2026

ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced positive results from the final analysis of the primary endpoint in Cohort A of QUILT-2.005 (NCT02138734), a randomized, controlled, registrational trial evaluating intravesical ANKTIVA® (nogapendekin alfa inbakicept-pmln/N-803) in combination with Bacillus Calmette-Guérin (BCG) versus BCG alone in patients with BCG-naïve, high-grade non-muscle invasive bladder cance.
Business Wire • Nov 9, 2026

ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
JERUSALEM & CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) (“ImmunityBio”) and Rafa Laboratories Ltd. (TASE: RAFA) (“Rafa”) today announced that the Israeli Ministry of Health (MoH) has granted approval for ANKTIVA® (nogapendekin alfa inbakicept), indicated in combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. Th.
Business Wire • Nov 9, 2026

¹ Disclosures

Open an M1 investment account to buy and sell ImmunityBio Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.